Precigen

PGEN

Market cap $1.07B

Overview Fund Activity

3.59 USD

-0.20

5.28%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

3.61

+0.02

0.56%

1 day

-5.28%

5 days

-13.08%

1 month

22.11%

3 months

133.12%

6 months

101.69%

Year to date

232.41%

1 year

259.07%

5 years

-32.14%

10 years

-92.12%

About: Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Employees: 25

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

44% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 32

7% more funds holding

Funds holding: 136 [Q1] → 145 (+9) [Q2]

0.49% more ownership

Funds ownership: 27.3% [Q1] → 27.8% (+0.49%) [Q2]

6% less capital invested

Capital invested by funds: $124M [Q1] → $116M (-$7.98M) [Q2]

48% less call options, than puts

Call options by funds: $964K | Put options by funds: $1.85M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

123% upside

Avg. target

$8.25

130% upside

High target

$8.5

137% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Jason N. Butler	$8	Market Outperform Maintained	19 Aug 2025
HC Wainwright & Co. Swayampakula Ramakanth	$8.5	Buy Reiterated	19 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about PGEN published over the past 30 days

The Motley Fool

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts

Investors in search of stocks that can produce dramatic gains in a short time frame will want to turn their heads toward the healthcare sector. A handful of stocks in the space more than doubled in price recently.

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts

Precigen Announces Up to $125 Million Non-Dilutive Financing

$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and other HPV-related indications GERMANTOWN, Md. , Sept. 2, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that it has entered into a credit facility agreement with investment funds managed by Pharmakon Advisors, LP.

Precigen Announces Up to $125 Million Non-Dilutive Financing

Precigen, Inc. - Special Call

Precigen, Inc. - Special Call Company Participants Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Presentation Swayampakula Ramakanth MD of Equity Research & Senior Healthcare Analyst Greetings, and thanks for joining us to have a conversation with Helen Sabzevari, Chief Executive Officer; and Phil Tennant, Chief Commercial Officer of Precigen.

Precigen, Inc. - Special Call

Zacks Investment Research

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

GERMANTOWN, Md. , Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that Precigen will participate in two upcoming virtual fireside chats hosted by Jennifer Kim of Cantor, and Swayampakula Ramakanth, PhD, of H.C.

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

This week's Undercovered Dozen highlights 12 lesser-known stocks and ETFs with compelling investment theses and recent catalysts. Standouts include CGDV's market-beating performance, DIVO's retirement risk management, and ONEOK's undervaluation and growth prospects. Speculative opportunities like Viking Therapeutics and Gorilla Technology offer high risk/reward, while Canadian Natural Resources and Rheinmetall present strong value and growth.

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

Precigen: This Billion-Dollar Approval Is Still Undervalued

PAPZIMEOS's full FDA approval for RRP is a decisive, de-risking event and validates Precigen's immunotherapy platform. PAPZIMEOS targets a significant unmet need, with potential for $1B+ peak sales, though logistical hurdles and launch friction exist. Precigen faces imminent financing needs due to limited cash runway and increased burn from its first commercial launch.

Precigen: This Billion-Dollar Approval Is Still Undervalued

Why Is Precigen Stock Surging On Friday?

On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.'s PGEN Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP).

Why Is Precigen Stock Surging On Friday?

US FDA approves Precigen's immunotherapy for rare respiratory disease

The U.S. Food and Drug Administration has approved Precigen's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regulator's nod.

US FDA approves Precigen's immunotherapy for rare respiratory disease

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FDA for the treatment of adults with RRP; a confirmatory clinical trial is no longer required RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection, which results in recurrent benign tumors in the respiratory tract; RRP affects an estimated 27,000 adult patients in the US PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11—the first and only approved therapy to treat the root cause of RRP Precigen will host a conference call on Monday, August 18 at 8:00 AM ET GERMANTOWN, Md , Aug. 15, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP.

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

See News Rankings

Charts implemented using Lightweight Charts™